Get Started

RIGL

NASD Rigel Pharmaceuticals, Inc.
Nov 4, 2026 · 9:56 PM ET EOD Market Closed

$51.29 ↑ +0.00 (+0.00%) Trading Up from the previous close of $51.29, $0.45 below the day’s high of $51.74

YTD change
+19.75%
vs 20-day SMA
+5.12%
vs 200-day SMA
+37.63%

Price ranges

Previous day
$46.88 $51.29
open $50.44 close $48.86
-$1.58 (-3.13%)
Today
$49.23 $51.74
open $50.57 now $51.29
+$0.72 (+1.42%)
Past week
$46.88 $52.61
from $50.55 now $51.29
+$0.74 (+1.46%)
Past month
$45.22 $52.61
from $46.11 now $51.29
+$5.18 (+11.23%)
This year
$24.95 $52.61
from $42.83 now $51.29
+$8.46 (+19.75%)

Price & Performance

+21.75 (+73.63%) / 6M

$24.01$33.83$43.66$53.48May 4Aug 5Nov 4

Signals & Sentiment

Momentum, market sentiment, and recent alerts

Very Good
  • The stock is 6.7% away from all-time highs of $55.00
  • RIGL is up 20% since the beginning of the year
  • RIGL is up 81% over the past 12 months
  • RIGL is up 11% over the past 1 month
  • 15% of all RIGL investors are betting against RIGL

RIGL reads very good: price sits above both the 20- and 200-day averages, the 12-month move is +80.7%.

Financial Strength

Earnings, valuation, and balance sheet

Earnings

Profitable Yes
EPS $0.88
Earnings momentum +4.4% Quarterly EPS growth
Quarterly change +4.4%

Valuation

P/E ratio 2.99
Enterprise value $900.8M
Beta 3.48

Balance sheet & scale

Income$321.9K
Revenue$276.8M
Cash$95.3M
Debt$40.0K
Income / Debt 8.06×

Company & Peers

Company profile and competitor comparison

Company profile

ExchangeNASD
Sector Manufacturing
Sub Sector Chemical Manufacturing
Market cap $958.1M

Rigel Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It discovers and develops novel, targeted drugs in the therapeutic areas of immunology, oncology and immune oncology. The firm focuses on intracellular signalling pathways and related targets that are critical to disease mechanisms. The company's products include Tavalisse, Fostamatinib and R835. Rigel Pharmaceuticals was founded by Donald G. Payan, James M. Gower, Thomas A. Raffin, Garry P. Nolan and Ronald B. Garren on June 14, 1996 and is headquartered in South San Francisco, CA.

Competitor comparison

TickerCompany PriceChange
LLY Eli Lilly and Company $1,417.99 +0.61%
JNJ Johnson & Johnson $276.32 +3.81%
ABBV AbbVie, Inc. $294.83 +3.09%
MRK Merck & Co., Inc. $150.36 +3.93%
RHHBY Roche Holding Ltd Sponsored ADR $60.94 +2.97%

You looked up one stock
Trade Ideas watches them all

Real-time scanning and AI-generated signals across the entire market.

See plans TI Pro Download

Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.